Stock 4534 MOCHIDA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mochida Pharmaceutical Co., Ltd.

Equities

4534

JP3922800002

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
3,130 JPY +0.97% Intraday chart for Mochida Pharmaceutical Co., Ltd. +3.81% -4.28%
04-25 Hidehiro Imatsu named president of Goldman Sachs Japan RE
03-21 Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Diversificatie en kansen: de Japanse markt in de schijnwerpers
Diversificazione e opportunità: il mercato giapponese sotto i riflettori
Diversifikation und Chancen: Der japanische Markt im Rampenlicht
Diversification et opportunités : Le marché japonais à l’honneur
Hidehiro Imatsu named president of Goldman Sachs Japan
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1%
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Mochida Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 30, 2023
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,080,000 shares, representing 2.96% for ¥3,500 million.
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Mochida Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.
Mochida Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4534 Stock
  4. News Mochida Pharmaceutical Co., Ltd.
  5. Other languages